What You Should Know
- The Funding: BrainCheck has raised an additional $13M in Series A financing, led by Next Coast Ventures, with participation from S3 Ventures and UPMC Enterprises.
- The Tech: The company’s flagship product, BrainCheck Assess™, is an FDA Class II digital cognitive assessment tool. It offers 29 validated screeners and care planning tools designed to integrate seamlessly into clinical workflows.
- The Traction: The platform is already highly embedded, used by more than 500 healthcare organizations nationwide. To date, clinicians have completed over 640,000 cognitive assessments using the system.
- The Strategy: The new capital will fund the expansion of BrainCheck’s enterprise cognitive care infrastructure. This includes deeper workflow integration, longitudinal patient monitoring, and AI-assisted analytics specifically tailored for risk-bearing and value-based care (VBC) environments.
The New Entry Point for Cognitive Care
Historically, a dementia diagnosis was a painstakingly slow process involving paper-based tests and months-long waits for specialist referrals. However, the landscape is shifting rapidly. The arrival of blood-based biomarkers and emerging targeted therapies for Alzheimer’s disease has created an urgent need for earlier, highly accurate risk stratification.
BrainCheck Assess™—the company’s FDA Class II digital cognitive assessment—is positioning itself as the critical front door to this new care continuum. By offering 29 validated cognitive screeners in both English and Spanish, the platform enables primary care doctors to establish objective, repeatable baselines for their patients in minutes.
Crucially, the platform is designed to reduce operational friction. It integrates directly into the Electronic Health Record (EHR), ensuring that the results seamlessly inform laboratory orders, specialty referrals, and structured follow-up care.
“UPMC clinicians have been evaluating BrainCheck for several years and have seen firsthand how standardized digital cognitive assessment can support them in real-world practice,” noted Adele Towers, M.D., M.P.H., a UPMC geriatrician and senior clinical advisor to UPMC Enterprises.
Aligning with Value-Based Care
The most strategic element of this $13M raise is how BrainCheck intends to deploy the capital. The company is actively shifting its focus toward Accountable Care Organizations (ACOs) and risk-bearing models.
In a value-based care environment, early detection of mild cognitive impairment (MCI) is not just a clinical imperative; it is a financial one. Managing cognitive health longitudinally across a large patient population prevents downstream hospitalizations and catastrophic care costs. To support this, BrainCheck is building out AI-assisted clinical infrastructure to analyze cognitive data at a population scale, while simultaneously partnering with collaborative care organizations to operationalize delivery for practices that lack in-house staffing.
“We are focused on reducing friction in cognitive assessment, supporting longitudinal care, and using AI responsibly to assist, never replace, clinical decision-making,” said Chris Loughlin, CEO of BrainCheck.
